Clinical Trial: RCT of GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07540390) titled 'RCT of GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.' on April 13.

Brief Summary: The investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk locoregionally advanced nasopharyngeal carcinoma (stage III, AJCC 9th edition). The aim is to obtain high-level, high-quality evidence-based data to clarify the efficacy and safety of combining chemoradiotherapy with PD-1 antibody and anlotinib, thereby providing a new treatment strategy ...